Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study

NCT01194453 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT01194453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01194453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
August 31, 2012
Enrollment
288 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, non-small cell lung cancer